Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01869803
Title Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Recruitment Approved for marketing
Gender both
Phase Phase I
Variant Requirements No
Sponsors Comprehensive Cancer Center of Wake Forest University

acute promyelocytic leukemia

acute myeloid leukemia


Gemtuzumab ozogamicin

Age Groups: adult
Covered Countries USA

No variant requirements are available.